GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed Mar 26, 2024 · 10-K · 86 days after period end · 0001493152-24-011332
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$2.96M | -$5.58M | -$18.02M | -$6.29M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Mar 26, 2024 · 86 d after period end
